Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Evan Cimino"'
Autor:
Xuejun Chen, Xiang Liu, Xiaohua Gong, Xing Liu, Swamy Yeleswaram, Evan Cimino, Ryan F. McGee, Michael E. Kuligowski
Publikováno v:
American Journal of Clinical Dermatology
Background Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c6efe61d4a982622ed87f102c2a8395
https://doi.org/10.1007/s40257-021-00610-x
https://doi.org/10.1007/s40257-021-00610-x
Autor:
Naresh Punwani, Evan Cimino, Swamy Yeleswaram, Noam Epstein, Phillip Wang, Robert R. Landman, Xuejun Chen, Brad Yuska, Kevin He, April M. Barbour
Publikováno v:
The Journal of Clinical Pharmacology. 59:1641-1647
Itacitinib is a potent, selective JAK-1 inhibitor currently in phase 3 development for the treatment of acute and chronic graft-versus-host disease (GVHD) in combination with corticosteroids. Itacitinib is primarily eliminated via metabolism by cytoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2da03cbaffc1aebf953a3425a2b00f
https://doi.org/10.1002/jcph.1484
https://doi.org/10.1002/jcph.1484
Autor:
Noam Epstein, Evan Cimino, Swamy Yeleswaram, Xuejun Chen, April M. Barbour, Gongfu Zhou, Kevin Rockich, Caterina Leonetti‐Whalen, Naresh Punwani
Publikováno v:
Journal of clinical pharmacologyReferences. 61(7)
Itacitinib is a potent, selective JAK-1 inhibitor currently in development for the treatment of chronic graft-vs-host-disease in combination with corticosteroids. Itacitinib is primarily eliminated via cytochrome P450 3A metabolism with minimal renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3936f74af3d06dd5ac428658676a0448
https://pubmed.ncbi.nlm.nih.gov/33434286
https://pubmed.ncbi.nlm.nih.gov/33434286